Phosphodiesterase type 4 (PDE4) inhibition: The search for effective therapy with minimal side effects

Progress in Respiratory Research

Volumn 39, Issue , 2010, Pages 269-278

  Yeadon, Mike ^a   Clarke, Nick ^a   Ward, Jon ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956475980     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000320830     Document Type: Article

References (24)

1. Barber R, Baillie GS, Bergmann R et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004, 287(2): L332-43.
2. Chambers RJ, Abrams K, Castleberry TA et al. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. Bioorg Med Chem Lett 2006, 16(3): 718-21. (Pubitemid 43014867)
3. Spina D. The potential of PDE4 inhibitors in asthma or COPD. Curr Opin Investig Drugs 2000, 1(2): 204-13.
4. Draheim R, Egerland U, Rundfeldt C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4- fluorobenzyl)-5- hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004, 308(2): 555-63.
5. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157(2): 351-70.
6. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109(3): 366-98.
7. Giembycz MA. Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 1996, 17(9): 331-6.
8. Manning CD, Burman M, Christensen SB et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999, 128(7): 1393-8.
9. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002, 99(11): 7628-33.
10. Hersperger R, Bray-French K, Mazzoni L, Muller T. Palladium-catalyzed crosscoupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors. J Med Chem 2000, 43(4): 675-82.
11. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5- hydroxyindole- 3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307(1): 373-85.
12. Raeburn D, Underwood SL, Lewis SA et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 1994, 113(4): 1423-31.
13. Barber R, Baillie GS, Bergmann R et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004, 287(2): L332-43.
14. Chambers RJ, Abrams K, Castleberry TA et al. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. Bioorg Med Chem Lett 2006, 16(3): 718-21. (Pubitemid 43014867)
15. Spina D. The potential of PDE4 inhibitors in asthma or COPD. Curr Opin Investig Drugs 2000, 1(2): 204-13.
16. Draheim R, Egerland U, Rundfeldt C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4- fluorobenzyl)-5- hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004, 308(2): 555-63.
17. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157(2): 351-70.
18. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109(3): 366-98.
19. Giembycz MA. Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 1996, 17(9): 331-6.
20. Manning CD, Burman M, Christensen SB et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999, 128(7): 1393-8.
21. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002, 99(11): 7628-33.
22. Hersperger R, Bray-French K, Mazzoni L, Muller T. Palladium-catalyzed crosscoupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors. J Med Chem 2000, 43(4): 675-82.
23. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5- hydroxyindole- 3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307(1): 373-85.
24. Raeburn D, Underwood SL, Lewis SA et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 1994, 113(4): 1423-31.